Allarity Therapeutics Announces Executive Leadership
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release ...
Source: globenewswire.com
Stever Carchedi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Stever Carchedi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Stever Carchedi Today - Breaking & Trending Today
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer Allarity Therapeutics A/S Press release Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA ® (ixabepilone) for the treatment of metastatic breast cancer. The U.S. Food and Drug Administration (FDA) approved IXEMPRA ®, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer. Allarity h...
Source: globenewswire.com
Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug
Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labeled "Variant of Concern 202012/01" by Public Health England (PHE), an agency o...
Source: news-medical.net
NAU to test Allarity drug against highly infectious Coronavirus Variant B117
E-Mail Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labelled "Variant of Concern 202012/01" by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on Decembe...
Source: eurekalert.org